IrniCann®

IrniCann®
Product Description

Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​ • An estimated 250,000 new cases of GBM per year worldwide.​1 • The preclinical studies demonstrated that IrniCan® was cytotoxic to Glioblastoma tumor and stem cells, reducing cell viability and inducing), which could establish a new benchmarkcaspase-dependent cell apoptosis (or cell death in treating GBM by improving safety and efficacy profiles.2

Read more Show less

Argent BioPharma ltd

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile

Argent BioPharma ltd

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile

More Products from Argent BioPharma ltd (2)

  • CimetrA®

    Product CimetrA®

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical and Clinical program, meeting FDA guidelines, to date: • Demon...
  • CannEpil

    Product CannEpil

    CannEpil®, one of Argent BioPharma's flagship products, is an enhanced iteration of a compounded isolated cannabinoid formulation. It leverages well-known historical data to become one of the first compounded prescription investigational drugs used for seizure management over the past years. The active ing...

Argent BioPharma ltd resources (1)